Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Proteome Sciences plc. (3/29/11). "Press Release: Proteome Sciences Closes Further Research Contract with Takeda".

Organisation Organisation Proteome Sciences plc
  Group Proteome Sciences (Group)
Products Product mass spectrometry services (MS services)
  Product 2 biomarker discovery services
Index term Index term Takeda–Proteome Sciences: protein biomarker services, 201103–– supply PS Biomarker Services provision of MS assays for disease related proteins
Person Person Pearce, Christopher (Proteome Sciences 201606– Non-executive Chairman before CEO)

Proteome Sciences plc ("Proteome") is pleased to announce that Takeda
Pharmaceutical Company Limited ("Takeda") has signed a further contract to use PS
Biomarker Services™. PS Biomarker Services™ will provide Takeda with mass spectrometric assays for disease related proteins.

Proteome has a strong track-record in the discovery / validation of peptide and protein
biomarkers and will apply its capabilities in assay development for the Takeda contract.
Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences

"PS Biomarker Services™ is ideally placed to undertake biomarker programmes at clinical/
preclinical stages and we are pleased to be working with Takeda on this new project".


For further information please contact:

Proteome Sciences plc Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer
James Malthouse, Finance Director
Dr. Ian Pike, Chief Operating Officer
Dr. Rainer Voegeli, Commercial Director

Nominated Adviser
Singer Capital Markets Limited Tel: +44 (0)20 3205 7500
Shaun Dobson/Claes Spång

Public Relations
IKON Associates Redleaf Communications Limited
Adrian Shaw Anna Dunkin/Lucy Salaman
Tel: +44 (0)1483 271291 Tel: +44 (0)20 7566 6700
Mobile:+44 (0)7979 900733 Email:

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity,
proprietary technologies for protein and peptide biomarker discovery, validation and assay development.
Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows
developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust
and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and
biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt,
Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed
assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in
larger validation studies and can be transferred for immunoassay development. The Company's own
research has discovered a large number of novel protein biomarkers in key human diseases and is
focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and
patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for
diagnostic and treatment applications that are available for license or are already outlicensed. Proteome
Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced
proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and
diagnostics companies.


Record changed: 2019-06-09


Picture [LSE] – The Business Web Portal 650x65px

More documents for Proteome Sciences (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top